OncoMatch/Clinical Trials/NCT02735057
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
Is NCT02735057 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Carboplatin for oesophagus cancer.
Treatment: Carboplatin — Management of elderly patient with cancer is a therapeutic challenge and a public health problem. The mean age of esophageal cancer is 64.5 years and 72.1 years in men and women respectively. Surgery is a standard treatment reserved to about 30 % of patients. The other 70 % are considered unfit for surgery for various reasons, including ageing. Chemoradiotherapy (CRT) is standard treatment for patients with esophageal cancer unfit for surgery. The validated treatment scheme is external beam radiotherapy (EBRT) 50 Gy over 5 weeks combined with cisplatin and 5FU infusion. However it induces high rates of severe and life threatening toxicities: grade 3 haematologic and esophageal mucositis of 20 and 25 % respectively, in patients with a median age of 64 years. CRT has not been properly evaluated in patients more than 75 years, and other combined chemotherapy are challenging.
Check if I qualifyExtracted eligibility criteria
Performance status
WHO 0–1
Lab requirements
Blood counts
adequate bone marrow reserve
Kidney function
normal renal function
Liver function
normal hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify